Fabry Disease Treatment Market
Regional Analysis
Europe Fabry
disease treatment market is expected to witness a drastic growth over the
forecast period, owing to penetration of key players in key regions of Europe
with their novel products for Fabry disease. For instance, Amicus Therapeutics
Inc. launched Galafold (Migalastat) for treatment of Fabry disease in Italy (in
March 2017) and in Spain (in January 2018)
In November 2018, JCR
Pharmaceuticals Co., Ltd, a Japan-based company launched biosimilar for
agalsidase beta for treatment of Fabry disease. Launch of biosimilars is
expected to increase affordability of these therapies in key regions of Asia
Pacific as biosimilars are quite cheaper than biologics, hence it is expected
to boost Asia Pacific Fabry disease treatment market growth.
Fabry disease also called as
Anderson-Fabry disease and alpha-galactosidase-A deficiency is an X-linked,
hereditary, lysosomal storage disease caused due to paucity of an enzyme α
galactosidase A (an enzyme required to metabolize lipids, fat-like substances
that include oils, waxes, and fatty acids). The mutated gene leads the
formation of lipids to harmful levels in various part of body such as the
autonomic nervous system, cardiovascular system, eyes, and kidneys. Some of the
common symptoms of this multisystem disorder include chronic pain,
acroparesthesia, gastrointestinal disturbances, characteristic skin lesions
(angiokeratomata), progressive renal impairment, cardiomyopathy, and stroke.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2326
Fabry Disease Treatment Market
Drivers
In recent past, various
regulatory bodies of key regions have approved novel medications for treatment
of Fabry disease. Approval and launch of such novel medications in the region
is expected to significantly support global Fabry disease treatment market growth
over the forecast period.
For instance, in August 2018,
Amicus Therapeutics, Inc., received the U.S. Food and Drug Administration (FDA)
approval for its drug Galafold (migalastat). It is the first oral medication
indicated for the treatment of adults with Fabry disease.
The presence of robust medication
pipeline indicated for treatment of Fabry disease is also expected to be a
major factor fueling growth of global Fabry disease treatment market over the
forecast period. Table mentioned below represents list of some novel therapies
in pipeline for Fabry disease treatment.
Furthermore, key players in the
market are majorly investing in development of novel therapies for Fabry
disease treatment, such strategic funding’s by various players is expected to
drastically fuel global Fabry Disease treatment market growth over the forecast
period. For instance, in February 2018, AvroBio Inc., closed US$ 60 million
financing to support the phase 2 study of its novel gene therapy, AVR-RD-01
underdevelopment for the treatment of Fabry disease.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/fabry-disease-treatment-market-2326
Fabry Disease Treatment Market
Restraint
Fabry disease is a very rare
disease affecting around 1 individual in 50,000 (according to the National
Fabry Disease Foundation), the diagnosis of Fabry disease is confirmed by
demonstrating an enzyme deficiency in males and by identifying the specific GLA
gene mutation in males and females.
Hence, low diagnostic rate due to
unavailability of such diagnostic procedures and trained professionals in
emerging economies such as Africa, India, and China are expected to be major
factor restraining global Fabry disease treatment market growth.
Fabry Disease Treatment Market
Key Players
Key players operating in global
Fabry disease treatment market include: Amicus Therapeutics Inc., Sanofi
Genzyme (Sanofi S.A. company), Idorsia Pharmaceuticals Ltd., Protalix
BioTherapeutics, Inc., AvroBio Inc., JCR Pharmaceuticals Co., Ltd., Resverlogix
Corp, and Ozmosis Research Inc.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2326
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment